ABSTRACT
INTRODUCTION The effective treatment of onychomycosis presents several signifi cant challenges for practitioners. The fi rst challenge is effective therapy, as the currently available antifungal drugs result in low to moderate effi cacy. The second challenge is drug administration periods. In the status quo, onychomycosis therapy is delivered daily or in pulse formats for several months. This requires a high level of patient compliance in order to achieve a fungicidal effect. The fi nal challenge is adverse effects associated with endogenous off-target binding and drug interactions. Many patients with onychomycosis have predisposing conditions such as diabetes, peripheral vascular disease or immunosupression that require polypharmacy. This can make it diffi cult to prescribe systemic therapy for onychomycosis to these individuals.
